

**JUBILANT PHARMA LIMITED**  
(Company Registration No. 200506887H)  
(Incorporated in the Republic of Singapore)  
Registered office: 80 Robinson Road, #02-00, Singapore 068898

February 1, 2021

**Singapore Exchange Securities Trading Limited**

11 North Buona Vista Drive #06-07  
The Metropolis Tower 2  
Singapore 138589

Dear Sirs,

**Subject: Appointment of Chief Financial Officer and change of name of the Holding Company**

We wish to inform you the following:

1. The Board of Directors of the Company has, at its meeting held on February 1, 2021, approved the appointment of Mr. Chris Krawtschuk as Chief Financial Officer of the Company effective from February 1, 2021.

Brief profile of Mr. Krawtschuk is given in **Annexure-A**.

2. Jubilant Life Sciences Limited, the holding company of the Company has undertaken a Composite Scheme of Arrangement involving amalgamation and demerger (the 'Scheme').

Pursuant to the Scheme, name of Jubilant Life Sciences Limited has been changed to Jubilant Pharmova Limited effective from today i.e. February 1, 2021.

This is for your information and records.

Thanking you,

Yours faithfully,  
For Jubilant Pharma Limited

Sd/-  
Shyam S. Bhartia  
Chairman and Managing Director

Encl.: As above

**Brief Profile - Mr. Chris Krawtschuk**

Mr. Chris Krawtschuk, 44 years, is B.Sc-Accounting and is a Certified Public Accountant from USA.

Mr. Chris Krawtschuk was working as the CFO of the US subsidiary of Morphosys, a listed company in German Stock Exchange with ADS in Nasdaq. This company, which specializes in developing NCEs/ NBEs for the global markets, has a revenue of USD 200 Million and employs ~ 150 employees.

Chris has worked for 15 years with PWC, US; first 6 years in the Audit practice and the remaining 9 years in Accounting Advisory and Capital Markets practice. He has assisted Verizon acquiring Bell labs; Pfizer acquiring Wyeth, selling the animal health product business for Pfizer; selling the nutrition business for Pfizer to Nestle and a number of capital raise transactions including convertibles, bonds, structured papers, etc. He was doing deals in conjunction with the M&A bankers. Subsequently, Chris joined Pfizer as a VP and Lead Divisional Controller to run the global accounting operations for commercial, manufacturing, R&D and treasury functions.

He has authored American Institute of CPA “Guide on IPR&D (Business Combinations and Asset Acquisitions)” and several PWC publications on business combinations and divestitures. He was awarded NYM Divestiture Service Leader for Capital Markets and Accounting Advisory Services (PwC).